Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Axial Spondyloarthritis - Overview
Axial Spondyloarthritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Axial Spondyloarthritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Axial Spondyloarthritis - Companies Involved in Therapeutics Development
Axial Spondyloarthritis - Drug Profiles
Axial Spondyloarthritis - Dormant Projects
Axial Spondyloarthritis - Discontinued Products
Axial Spondyloarthritis - Product Development Milestones
Featured News & Press Releases
Aug 17, 2022: NICE Recommends RINVOQ (upadacitinib) as a treatment option for active ankylosing spondylitis (AS) in adults
Aug 08, 2022: Lilly’s Taltz (ixekizumab) now available in new, citrate-free formulation to reduce injection site pain for improved patient experience
Jul 29, 2022: RINVOQ (upadacitinib) approved by European Commission as an oral treatment for adults with active non-radiographic axial spondyloarthritis
Jul 27, 2022: Mabpharm announces approval of clinical trial application of CMAB015 by the tiol Medical Products Administration of Chi
Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
Jul 20, 2022: Health Cada approves AbbVie’s RINVOQ? (upadacitinib) for the treatment of adults with active ankylosing spondylitis
Jun 27, 2022: CHMP recommends approval of Upadacitinib (RINVOQ) for the treatment of adults with active non-radiographic axial spondyloarthritis
Jun 01, 2022: AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ?) in Patients with Axial Spondyloarthritis at EULAR 2022
Jun 01, 2022: AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ?) in Patients with Axial Spondyloarthritis at EULAR 2022
May 23, 2022: First presentations of phase 3 data for Bimekizumab across the full spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022
May 02, 2022: FDA grants approval for AbbVie’s Rinvoq to treat ankylosing spondylitis
Apr 11, 2022: Celltrion Healthcare announces the availability of Yuflyma, a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar in Cada
Jan 20, 2022: Lynk doses first patient in Phase II ankylosing spondylitis drug trial
Jan 18, 2022: Positive top-line results for bimekizumab in phase 3 non-radiographic axial spondyloarthritis study
Jan 07, 2022: AbbVie submits applications for Upadacitinib (RINVOQ) in non-radiographic axial spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Axial Spondyloarthritis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Axial Spondyloarthritis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Axial Spondyloarthritis - Dormant Projects, 2022
Axial Spondyloarthritis - Dormant Projects, 2022 (Contd..1)
Axial Spondyloarthritis - Dormant Projects, 2022 (Contd..2)
Axial Spondyloarthritis - Dormant Projects, 2022 (Contd..3)
Axial Spondyloarthritis - Discontinued Products, 2022